broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K66175015-001-12-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.072414 | 3.15943 | 0.303077 | 0.9014 | 3.608933 | 3.792156 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000946 |
BRD-K67844266-003-01-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.085584 | 4.228624 | 0.728254 | 0.749691 | 0.701929 | 0.733796 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000946 |
BRD-K69001009-001-02-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.959568 | -2.781907 | 0.063539 | 0.969166 | 0.999602 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000946 |
BRD-K69694239-001-02-2 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.1438 | 3.652006 | 0.659014 | 0.834986 | 0.503535 | 0.552531 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000946 |
BRD-K69776681-001-03-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.160398 | 0.796887 | 0.546637 | 0.620907 | 0.127634 | 0.20739 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000946 |
BRD-K70301465-001-05-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.651498 | -0.186699 | 0.20387 | 1 | 0.032902 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000946 |
BRD-K70401845-001-15-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.784076 | 4.33963 | 0.437586 | 0.955054 | 1.326464 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000946 |
BRD-K73838513-003-05-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.71519 | 0.441848 | -0.142372 | 0.80285 | 0.006743 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000946 |
BRD-K75009076-001-02-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.369857 | 3.579833 | 0.267779 | 0.863681 | 1.225479 | 1.784824 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000946 |
BRD-K76210423-001-01-6 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.562995 | -0.176695 | -0.069224 | 1 | 0.005292 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000946 |
BRD-K76239644-001-02-6 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.707073 | -0.01057 | -0.091602 | 0.856704 | 0.001302 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000946 |
BRD-K76674262-001-03-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.124959 | 4.242756 | 0.737844 | 0.541074 | 0.061597 | 0.065917 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000946 |
BRD-K77625799-001-07-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.763729 | 2.951772 | 0.40722 | 0.802236 | 0.002957 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000946 |
BRD-K78431006-001-15-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.452091 | 4.688528 | 0.450651 | 0.909085 | 1.998508 | 3.295719 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000946 |
BRD-K79254416-001-21-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.400182 | 1.507601 | 0.567594 | 0.760214 | 0.206972 | 0.602653 | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000946 |
BRD-K81016934-001-02-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.672876 | 0.343927 | 0.010014 | 0.849283 | 0.136595 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000946 |
BRD-K81418486-001-44-2 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.034665 | 1.713222 | 0.773814 | 0.879869 | 3.233956 | 3.372513 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000946 |
BRD-K81473043-001-19-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.067367 | 2.446844 | 0.803303 | 0.679881 | 0.022345 | 0.023707 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000946 |
BRD-K82135108-001-04-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.008023 | 0.719845 | 0.652908 | 0.668575 | 0.035336 | 0.034564 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000946 |
BRD-K82746043-001-19-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.164097 | 0.41625 | 0.541425 | 0.572861 | 0.196135 | 0.099181 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000946 |
BRD-K82818427-001-04-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.279287 | 3.082293 | 0.272056 | 1 | 0.133395 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000946 |
BRD-K83029223-001-01-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.138853 | 1.423154 | 0.82634 | 0.434171 | 0.001056 | 0.001327 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000946 |
BRD-K83988098-001-02-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.258838 | 0.654938 | 0.787622 | 0.69366 | 0.020936 | 0.011073 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000946 |
BRD-K85402309-043-01-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.419036 | 0.4493 | -0.253568 | 0.792431 | 0.204439 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000946 |
BRD-K86118762-001-01-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.925699 | 0.069761 | -0.03579 | 0.962203 | 0.094491 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000946 |
BRD-K86972824-001-01-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.87872 | 0.71664 | 0.009537 | 0.955649 | 0.316913 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000946 |
BRD-K87737963-001-06-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.98272 | 0.264173 | -0.016086 | 0.993278 | 0.254571 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000946 |
BRD-K87782578-001-01-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.175832 | 3.368021 | 0.871627 | 0.895744 | 2.943944 | 3.348244 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000946 |
BRD-K87909389-003-03-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.141366 | 4.052095 | 0.795925 | 0.622003 | 0.064203 | 0.069692 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000946 |
BRD-K88510285-001-17-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.398128 | 4.264054 | 0.427837 | 0.772726 | 0.064116 | 0.09311 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000946 |
BRD-K89014967-001-04-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.090762 | 1.230817 | 0.060847 | 1 | 0.336812 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000946 |
BRD-K92441787-001-04-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.71095 | -0.076049 | -0.069451 | 0.849697 | 0.226309 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000946 |
BRD-K92723993-001-17-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.012937 | -0.114682 | -0.001293 | 1 | 25.847012 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000946 |
BRD-K95142244-001-01-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.561708 | 1.998706 | 0.185778 | 0.734604 | 0.028043 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000946 |
BRD-K96123349-236-02-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.329091 | 9.690935 | 0.549814 | 0.857595 | 1.274706 | 1.424049 | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000946 |
BRD-K98572433-001-02-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.560499 | 0.172103 | -0.210721 | 0.719662 | 0.002423 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000946 |
BRD-K99113996-001-02-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.311988 | -1.081975 | 0.335937 | 0.93634 | 0.000965 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000946 |
BRD-K99616396-001-05-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.766194 | 0.132495 | -0.027351 | 0.872749 | 0.019545 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000946 |
BRD-M97302542-001-04-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.061791 | 0.505589 | -0.20924 | 1 | 0.280854 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000946 |
BRD-A25234499-001-19-1 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.832131 | -0.515418 | -0.119495 | 0.894673 | 0.342324 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000947 |
BRD-A70858459-001-01-7 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 1.104696 | -0.548619 | -0.002256 | 1 | 0.002089 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000947 |
BRD-A74914197-001-02-9 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.433077 | 5.755094 | 0.321712 | 0.72372 | 0.005518 | 0.007826 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000947 |
BRD-K02113016-001-19-6 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.434255 | 0.655938 | 0.497164 | 0.758145 | 0.168172 | 3.707129 | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000947 |
BRD-K02130563-001-11-4 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.038967 | 0.418758 | 0.763997 | 0.353807 | 0.008275 | 0.010044 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000947 |
BRD-K03390685-001-01-7 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.543621 | 8.156294 | 0.347073 | 0.838775 | 0.324401 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000947 |
BRD-K03406345-001-21-1 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | -1.349956 | -1.88357 | 0.140058 | 0.976797 | 0.000258 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000947 |
BRD-K03449891-001-08-6 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.064261 | 0.702279 | 0.725404 | 0.647449 | 0.283478 | 0.344816 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000947 |
BRD-K03765900-001-01-9 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.366665 | 0.433694 | 0.269165 | 0.754463 | 0.31976 | 6.736061 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000947 |
BRD-K05804044-001-18-5 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.387281 | 0.838443 | 0.43216 | 0.812173 | 0.56337 | 3.329879 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000947 |
BRD-K06814349-304-02-7 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.631625 | 0.222255 | -0.353305 | 0.695085 | 0.000038 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000947 |
BRD-K08109215-001-06-4 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.319356 | 0.024748 | 0.030177 | 0.649777 | 0.007413 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000947 |
BRD-K08542803-001-02-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.30507 | 2.962532 | 0.436417 | 0.716642 | 0.19119 | 0.262757 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000947 |
BRD-K08547377-001-04-4 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.793137 | -0.037986 | -0.020248 | 0.898564 | 0.028199 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000947 |
BRD-K08703257-001-13-9 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 39.740888 | 0.127389 | -0.019336 | 1 | 710,292,935,100,460,100,000,000,000,000 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000947 |
BRD-K08799216-001-05-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 2.777921 | 0.315991 | -0.773824 | 1 | 198.33335 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000947 |
BRD-K09951645-001-11-8 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 1.225809 | 0.031828 | 0.00187 | 1 | 0.000342 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000947 |
BRD-K11267252-001-05-1 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 1.073276 | 0.420218 | -0.198348 | 1 | 0.091928 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000947 |
BRD-K11630072-001-13-2 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.332469 | 0.363277 | -0.033208 | 0.685201 | 0.115389 | 2.34078 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000947 |
BRD-K12184916-001-19-6 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.392972 | 2.134605 | 0.541653 | 0.48353 | 0.002472 | 0.005089 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000947 |
BRD-K12343256-001-14-7 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.668728 | -0.240823 | -0.110658 | 0.868522 | 0.011359 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000947 |
BRD-K13049116-001-04-0 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.560913 | -0.096663 | 0.082511 | 0.778235 | 0.096661 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000947 |
BRD-K13390322-001-06-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.203213 | 5.303819 | 0.66341 | 0.790605 | 0.780528 | 0.861183 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000947 |
BRD-K13662825-001-07-5 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.130784 | 1.611013 | 0.678794 | 0.564749 | 0.019418 | 0.023439 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000947 |
BRD-K15179879-001-03-2 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.145969 | 11.977632 | 0.894735 | 0.451063 | 0.019543 | 0.020114 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000947 |
BRD-K15600710-066-05-8 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.048733 | 0.85125 | 0.55536 | 0.657621 | 0.315722 | 0.356142 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000947 |
BRD-K16730910-001-10-7 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.137358 | 1.206626 | 0.669881 | 0.81398 | 1.321728 | 1.724857 | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000947 |
BRD-K17555800-003-02-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.970835 | -0.63128 | 0.015797 | 0.98177 | 0.30029 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000947 |
BRD-K17610631-001-03-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.10173 | 1.058108 | 0.883573 | 0.535617 | 0.064039 | 0.079398 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000947 |
BRD-K17743125-001-08-4 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.590743 | 5.961756 | 0.726996 | 0.748306 | 0.025584 | null | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000947 |
BRD-K17894950-001-14-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.995063 | -0.36262 | -0.038857 | 0.996284 | 3.31792 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000947 |
BRD-K18961567-001-01-1 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.891148 | -0.003633 | -0.005865 | 0.945467 | 0.229462 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000947 |
BRD-K19540840-001-09-4 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.983527 | -0.13473 | -0.00624 | 0.990152 | 1.63873 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000947 |
BRD-K19687926-001-04-1 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.875441 | -0.186204 | -0.030195 | 0.923424 | 1.134233 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000947 |
BRD-K22064724-001-01-8 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.029053 | 0.675115 | 0.503429 | 0.564134 | 0.133434 | 0.145806 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000947 |
BRD-K23228615-001-02-8 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.200789 | 0.382285 | 0.570514 | 0.584651 | 0.06009 | 0.230208 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000947 |
BRD-K23984367-001-07-5 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.213623 | 2.880439 | 0.453981 | 0.899225 | 2.91164 | 3.533163 | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000947 |
BRD-K26026438-001-01-0 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.343394 | 0.29526 | -0.253451 | 0.76472 | 0.771326 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000947 |
BRD-K26657438-001-15-2 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 1.007723 | 0.353751 | -0.136132 | 1 | 0.915725 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000947 |
BRD-K28822270-001-03-7 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.191231 | 0.888462 | 0.934559 | 0.57535 | 0.063691 | 0.109569 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000947 |
BRD-K29905972-001-06-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.322265 | 1.038649 | 0.589356 | 0.715943 | 0.173174 | 0.468777 | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000947 |
BRD-K31698212-001-02-9 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 1.911558 | -0.37271 | -0.352878 | 1 | 0.011663 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000947 |
BRD-K31928526-001-02-1 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.534718 | 2.910554 | 0.474097 | 0.788025 | 0.120189 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000947 |
BRD-K33379087-001-07-5 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.56972 | 0.039004 | -0.052041 | 0.779516 | 0.021766 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000947 |
BRD-K33610132-001-02-9 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.587037 | 0.095861 | -0.185178 | 0.776427 | 0.013411 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000947 |
BRD-K33622447-066-01-9 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 1.085355 | -2.429005 | -0.153236 | 1 | 1.30958 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000947 |
BRD-K35520305-001-16-9 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.733382 | -3.914231 | 0.143286 | 0.878541 | 0.050739 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000947 |
BRD-K36627727-001-05-4 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 1.320326 | -0.357174 | 0.052741 | 1 | 0.008805 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000947 |
BRD-K36788280-001-01-2 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.704427 | 0.207296 | 0.034439 | 0.853277 | 0.084201 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000947 |
BRD-K37379014-001-02-0 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.402717 | 0.316341 | 0.071041 | 0.649898 | 0.00033 | 0.058344 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000947 |
BRD-K38332599-001-01-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.039268 | 0.312916 | 0.926584 | 0.546181 | 0.118747 | 0.15422 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000947 |
BRD-K38527262-300-01-0 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.185982 | 3.555393 | 0.567657 | 0.858638 | 1.707797 | 1.946506 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000947 |
BRD-K38852836-001-02-1 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.34583 | 4.798324 | 0.543824 | 0.740085 | 0.052958 | 0.067674 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000947 |
BRD-K39974922-001-04-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.358403 | 0.697694 | 0.226063 | 0.719339 | 0.149773 | 0.913603 | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000947 |
BRD-K41859756-001-06-8 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.287127 | 6.819179 | 0.614437 | 0.643706 | 0.019596 | 0.022209 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000947 |
BRD-K42495768-001-01-7 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.532449 | 0.351593 | 0.132064 | 0.836581 | 0.678314 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000947 |
BRD-K42805893-001-04-9 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.795918 | -0.445042 | -0.224369 | 0.864023 | 0.631665 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000947 |
BRD-K42828737-001-03-3 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.625029 | 0.286423 | 0.107591 | 0.808058 | 0.064464 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000947 |
BRD-K42898655-001-01-8 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.301029 | 0.458395 | 0.271625 | 0.429635 | 0.000068 | 0.000506 | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000947 |
BRD-K43389675-001-02-1 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | -0.208123 | 0.26084 | 0.745567 | 0.417613 | 0.106595 | 0.028074 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000947 |
BRD-K44227013-001-06-4 | ACH-000947 | OVK18_OVARY | MTS010 | 1 | 0.411144 | 2.421214 | 0.563292 | 0.692461 | 0.062925 | 0.128441 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000947 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.